 |
|
Ribavirin and Use of Clotting Factors in Patients With Hemophilia and Chronic Hepatitis C
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: Ribavirin has been used in combination with interferon (IFN) alfa to treat chronic hepatitis C. This combination therapy has been reported to be more effective than IFN monotherapy for eradicating hepatitis C virus (HCV),1-3 including that occurring in patients with concomitant hemophilia.4-5 We are unaware of previous reports of reduction in the use of clotting factors in HCV-positive patients with hemophilia treated with ribavirin and IFN.
Methods
Eight consecutive patients with hemophilia were treated as outpatients for HCV infection with IFN and ribavirin between June 2002 and November 2003 at Nagoya University Hospital (Table). All patients were men with a mean (SD) age of 44.8 (10.0) years. Six patients had hemophilia A, and 2 had hemophilia B. Hemophilia was severe in 3 patients, moderate in 2, and mild in 3. Four patients (patients 1, 2, 3, and 5) had been previously treated with IFN alfa-2b . . . [Full Text of this Article]
Takashi Honda, MD, PhD;
Hidenori Toyoda, MD, PhD;
Kazuhiko Hayashi, MD, PhD;
Yoshiaki Katano, MD, PhD;
Motoyoshi Yano, MD, PhD;
Isao Nakano, MD, PhD;
Kentaro Yoshioka, MD, PhD;
Hidemi Goto, MD, PhD
Department of Gastroenterology
Nagoya University School of Medicine
Nagoya, Japan
Koji Yamamoto, MD, PhD;
Junki Takamatsu, MD, PhD
jtkmtsu@med.nagoya-u.ac.jp
Department of Transfusion Medicine
Nagoya University School of Medicine
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
What's new in the other general journals
Tonks
BMJ 2005;330:623-624.
FULL TEXT
|
